|
| 38079455 | Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: Prospective phase 2 MARCIE trial. | Neuro Oncol | 2024 |
| 37850576 | Mesonephric-like adenocarcinoma harbours characteristic copy number variations and a distinct DNA methylation signature closely related to mesonephric adenocarcinoma of the cervix. | J Pathol | 2024 |
| 37494539 | Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial. | Clin Cancer Res | 2023 |
| 36239925 | Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. | Neuro Oncol | 2023 |
| 35609569 | Dysfunctional dendritic cells limit antigen-specific T cell response in glioma. | Neuro-Oncology | 2023 |
| 36437415 | Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification. | Acta Neuropathol | 2023 |
| 36377252 | Clinical implementation of integrated molecular-morphologic risk prediction for meningioma. | Brain Pathol | 2023 |
| 35977048 | BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. | Neuro Oncol | 2023 |
| 37855895 | Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042-26042. | Acta Neuropathol | 2023 |
| 37853454 | INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas. | Neurol Res Pract | 2023 |
| 37605249 | Diagnostic accuracy of a minimal immunohistochemical panel in at/rt molecular subtyping, correlated to dna-methylation profiling. | Acta Neuropathol Commun | 2023 |
| 37936247 | EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma. | | 2023 |
| 38026572 | Reference on copy number variations in pleomorphic xanthoastrocytoma: Implications for diagnostic approach. | Free Neuropathol | 2023 |
| 37737691 | A Novel Type of IDH-wildtype Glioma Characterized by Gliomatosis Cerebri-like Growth Pattern, TERT Promoter Mutation, and Distinct Epigenetic Profile. | Am J Surg Pathol | 2023 |
| 37735561 | A H3K27M-targeted vaccine in adults with diffuse midline glioma. | Nat Med | 2023 |
| 37999877 | Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow. | J Neurooncol | 2023 |
| 37641393 | Precision cancer medicine: Concepts, current practice, and future developments. | J Intern Med | 2023 |
| 37556934 | Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma. | Gynecol Oncol | 2023 |
| 37555357 | DNA methylation profile discriminates sporadic giant cell granulomas of the jaws and cherubism from their giant cell-rich histological mimics. | | 2023 |
| 37093271 | Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes. | Acta Neuropathol | 2023 |
| 36716920 | Identification of Epigenetically Regulated Genes Distinguishing Intracranial from Extracranial Melanoma Metastases. | | 2023 |
| 37474126 | Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in isocitrate dehydrogenase mutant glioma. | Neuro Oncol | 2023 |
| 37277265 | Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419). | Eur J Cancer | 2023 |
| 36966138 | Genomic characterization of DICER1-associated neoplasms uncovers molecular classes. | Nat Commun | 2023 |
| 36964296 | Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature. | NPJ Precis Oncol | 2023 |
| 36959034 | Corrigendum to 'Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry' [Eur J Cancer 180 (2023) 71-84]. | Eur J Cancer | 2023 |
| 37075810 | LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients. | Neuro Oncol | 2023 |
| 36635768 | Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses. | Acta Neuropathol Commun | 2023 |
| 37392767 | Detailed molecular and pathological analyses of primary intracranial embryonal rhabdomyosarcoma with a BRAF mutation: illustrative case. | | 2023 |
| 37188167 | Clinical outcome following surgical resection and radiotherapy in adult patients with pleomorphic xanthoastrocytoma as defined by DNA methylation profiling. | Neurooncol Pract | 2023 |
| 37379234 | Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. | Neuro Oncol | 2023 |
| 36933012 | Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions. | Acta Neuropathol | 2023 |
| 36542877 | Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry. | Eur J Cancer | 2023 |
| 37432627 | The Epigenetic Landscape of Meningiomas. | Adv Exp Med Biol | 2023 |
| 37173969 | Risk Estimation in Non-Enhancing Glioma: Introducing a Clinical Score. | | 2023 |
| 36928815 | Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. | Nat Med | 2023 |
| 37296499 | Simultaneous Nbs1 and p53 inactivation in neural progenitors triggers high-grade gliomas. | Neuropathol Appl Neurobiol | 2023 |
| 36459208 | Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts. | Acta Neuropathol | 2023 |
| 37293256 | Analysis of recurrence probability following radiotherapy in patients with CNS WHO grade 2 meningioma using integrated molecular-morphologic classification. | Neurooncol Adv | 2023 |
| 36788095 | High-Grade Endometrial Stromal Sarcomas With YWHAE::NUTM2 Gene Fusion Exhibit Recurrent CDKN2A Alterations and Absence of p16 Staining is a Poor Prognostic Marker. | Mod Pathol | 2023 |
| 36786841 | Correction to: Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification. | Acta Neuropathol | 2023 |
| 35322237 | Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. | Nat Rev Clin Oncol | 2022 |
| 35771282 | Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression. | Acta Neuropathol | 2022 |
| 36303507 | Adult cerebellar glioblastoma categorized into a pediatric methylation class with a unique radiological and histological appearance: illustrative case. | | 2022 |
| 36240081 | Opinion & Special Article: Glioma Classification: How to Interpret Molecular Markers in a Diffuse Glioma Pathology Report. | Neurology | 2022 |
| 35388566 | Methylation classifiers: Brain tumors, sarcomas, and what's next. | Genes Chromosomes and Cancer | 2022 |
| 35511748 | HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma. | Neuro Oncol | 2022 |
| 35380708 | Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. | Neuro Oncol | 2022 |
| 35499168 | Endometrial Stromal Sarcomas With BCOR Internal Tandem Duplication and Variant BCOR/BCORL1 Rearrangements Resemble High-grade Endometrial Stromal Sarcomas With Recurrent CDK4 Pathway Alterations and MDM2 Amplifications. | Am J Surg Pathol | 2022 |
| 35430765 | Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. | Genes Chromosomes Cancer | 2022 |